AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...
FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...
The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license ...
IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...
The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...
Regeneron reached an agreement with the U.S. government to link current and future drug prices to those in other developed ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
This episode of The Ron Lanton Report explores how geography, policy, and capital are converging to redefine where innovation ...
Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...
Radiopharmaceutical pipelines are broadening beyond prostate cancer into multitumor programs, pairing alpha/beta emitters with immunotherapy or DDR agents and driving investments in isotope supply, ...
FDA Expands Approval for Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria
Pediatric approval leveraged CupidKids pharmacokinetic bridging and safety assessments, with adverse events consistent across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results